Objective To analyze the correlation of general clinical characteristics(age and gender),laboratory determination results with prognosis(efficacy,recurrence and survival time)in patients with core binding factor(CBF)-related acute myeloid leukemia(AML),and to provide a reference for optimizing clinical treatment plans.Methods A total of 116 CBF-AML patients who received standard induction and consolidation chemotherapy at Shanghai General Hospital from January 2014 to December 2021 were enrolled,including 77 cases who received allogeneic hematopoietic stem cell transplantation(allo-HSCT).According to fusion genes,the subjects were classified into AML RUNX1::RUNX1T1(Group 1)and AML CBFB::MYH11(Group 2).Kaplan-Meier survival analysis and Cox regression analysis were used to evaluate the prognostic factors.Results There was statistical significance in baseline characteristics between Group 1 and Group 2,including age at onset,peripheral blood white blood cell count,hemoglobin level,bone marrow blast percentage,incidence of additional chromosomal abnormalities,sex chromosome deletion,KRAS mutation and NRAS mutation(P<0.05).The overall survival(OS)of patients with recurrence was lower than that of those without recurrence(P=0.008).Male,recurrence,TET2 mutation and del(9q)were related with poor OS(P<0.05).Patients with platelet count<20×109·L-1 had poor OS and relapse-free survival(RFS)(P<0.05).The OS of patients who recurred after transplantation was worse than that of patients who did not recurr after transplantation(P=0.001).Cox regression analysis showed that recurrence,TET2 mutation and chromosome del(9q)were risk factors for OS,and time to remission(days)was an independent influencing factor for OS in AML patients with RUNX1::RUNX1T1(P=0.038).The proportion of bone marrow blast percentage was an independent influencing factor for OS in AML patients with CBFB::MYH11(P=0.044).Conclusions There is heterogeneity in baseline characteristics between the 2 fusion genes of CBF-AML patients.TET2 mutation and del(9q)significantly affect survival time.AML patients with RUNX1::RUNX1T1 should pay attention to the time to remission(days),recurred patients are recommended to undergo salvage transplantation in time,and CBFB::MYH11 patients should pay attention to the bone marrow blast percentage.
NETL
NSTL
万方数据
